REGENXBIO (NASDAQ:RGNX) Releases Quarterly Earnings Results, Beats Expectations By $0.67 EPS

REGENXBIO (NASDAQ:RGNX) released its earnings results on Thursday. The biotechnology company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.67, FiscalAI reports. The firm had revenue of $9.16 million during the quarter, compared to analyst estimates of $10.89 million. REGENXBIO had a negative net margin of 112.58% and a negative return on equity of 220.07%.

Here are the key takeaways from REGENXBIO’s conference call:

• Sura-vec wet AMD pivotal results are expected this quarter. The two trials enrolled more than 1,300 patients and are testing non-inferiority to anti-VEGF controls; the company and AbbVie expect global regulatory submissions in 2027. Results remain a significant upcoming catalyst.
• RGX-202 is advancing toward a planned Q1 2027 BLA filing under the accelerated approval pathway, with potential U.S. approval in the second half of 2027. Management cited safety data from more than 60 patients and a correlation between microdystrophin levels and functional improvement, but FDA feedback and review remain key uncertainties.
• Sura-vec is also progressing in diabetic retinopathy. The pivotal NAAVIGATE study is enrolling, and management reported that 60% of patients at the same dose in the Phase II ALTITUDE study improved by at least two retinopathy severity steps at three years without additional treatment.
• Regenxbio reported $251 million in cash, equivalents and marketable securities at quarter-end and guided to a runway through late Q4 2027, beyond several stated milestones. The balance benefited from a $100 million AbbVie milestone and $108 million in public offering proceeds; the runway estimate excludes potential additional funding and the $39 million Sarepta settlement payment received in October.

REGENXBIO Stock Performance

Shares of REGENXBIO stock traded up $0.24 on Friday, reaching $7.62. 1,186,482 shares of the stock were exchanged, compared to its average volume of 1,316,993. REGENXBIO has a one year low of $5.45 and a one year high of $16.19. The firm has a market cap of $503.00 million, a PE ratio of -2.37 and a beta of 1.24. The firm’s 50 day moving average is $7.80 and its 200-day moving average is $9.06.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Barclays cut REGENXBIO from an “overweight” rating to a “hold” rating in a research note on Friday, August 7th. HC Wainwright reiterated a “buy” rating on shares of REGENXBIO in a report on Monday, September 28th. Morgan Stanley reissued an “overweight” rating and set a $18.00 price target on shares of REGENXBIO in a research report on Friday, August 7th. Zacks Research upgraded shares of REGENXBIO from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Finally, UBS Group reissued a “positive” rating on shares of REGENXBIO in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.83.

REGENXBIO Company Profile

REGENXBIO Inc (NASDAQ: RGNX) is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company’s programs use adeno-associated virus (AAV) vectors to deliver genetic material to targeted cells, with the goal of addressing the underlying causes of disease rather than primarily treating symptoms.

REGENXBIO’s technology is built around its NAV AAV Technology Platform, which supports the design and development of gene-delivery vectors. Its pipeline has included investigational therapies for conditions such as Duchenne muscular dystrophy, Hunter syndrome, age-related macular degeneration and other rare diseases.